Ultime notizie per Aurora Innovation (NASDAQ:AUR) Azioni

Aurora Innovation

Aurora Innovation Inc delivers self-driving technology safely, quickly, and broadly. The Aurora Driver is a self-driving system designed to operate multiple vehicle types, from freight-hauling trucks to ride-hailing passenger vehicles. It underpins Aurora Horizon and Aurora Connect, its driver-as-a-service products for trucking and ride-hailing. The Company is developing the Aurora Driver, an advanced and scalable suite of self-driving hardware, software, and data services designed as a platform to adapt and interoperate among vehicle types and applications.

Aurora Innovation, Inc. - Class A Common Stock

Aurora Innovation Inc

Aura Biosciences Inc

AURORA ACQUISITION CORP CL A

Auri Inc

AURUM MEGAMETALS CORP by Aurum Megametals Corp.

Aurum Megametals Corp

Aurion Biotech Inc

Aurora - United States Dollar

AURELIUS MINERALS INC by Aurelius Minerals Inc.

Aurelius Minerals Inc

Attune RTD

Aurwest Resources Corp

NUO THERAPEUTICS INC NEW by Nuo Therapeutics, Inc.

Nuo Therapeutics Inc

Aurory

This strategic alliance addresses the urgent and growing need for skilled labor within the electrical sector by providing contractors with immediate access to qualified workers while supporting long-term workforce development initiatives.

News

General

TrueBlue announced that PeopleReady Skilled Trades, a specialized division of its brand PeopleReady, has been named the Official Professional Staffing and Labor Provider for Independent Electrical Contractors, a nonprofit federation representing over 4,100 member businesses with 53 educational campuses and local chapters nationwide

Evercore ISI Group analyst Steve Sakwa maintains Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) with a In-Line and lowers the price target from $111 to $106.

Price Target

Analyst Ratings

Evercore ISI Group Maintains In-Line on Prologis, Lowers Price Target to $106

HBAN

Huntington Bancshares Approved A $1B Share Repurchase Authorization

Laidlaw &amp; Co. analyst Yale Jen downgrades icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) from Buy to Hold.

Downgrades

ICAD

Laidlaw & Co. Downgrades icad to Hold

Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.31 by 9.68 percent. The company reported quarterly sales of $1.920 billion which beat the analyst consensus estimate of $1.886 billion by 1.82 percent. This is a 9.46 percent increase over sales of $1.754 billion the same period last year.

Earnings

Earnings Beats

Huntington Bancshares Q1 2025 GAAP EPS $0.34 Beats $0.31 Estimate, Sales $1.920B Beat $1.886B Estimate

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) on Thursday&nbsp;reported first-quarter 2025 earnings and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44858844/unitedhealth-group-reports-first-quarter-2025-results-and-revises-full-year-guidance" rel="noreferrer noopener">revised 2025 guidance</a>.
The insurance giant reported adjusted EPS of $7.20, up from $6.91 a year ago, missing the consensus of $7.29. Revenues increased 6.8% year over year to $109.6 billion, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $111.60 billion</a>.
&#8220;UnitedHealth Group&#8230;did not perform up to our expectations, and we are aggressively addressing those challenges to position us well for the years ahead and return to our long-term earnings growth rate target of 13 to 16%,&#8221; said Andrew Witty, chief executive officer of UnitedHealth Group.
The first quarter medical care ratio was 84.8% compared to 84.3% in 2024.
<ul>
<li>The increase was primarily due to the revenue effects of the ongoing Medicare funding reductions and member mix and the higher senior care activity, partially offset by the Medicare Part D program changes, which affected seasonality.</li>
<li>The company did not reflect any favorable earnings impacting medical reserve development in the quarter.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/general/health-care/25/04/44821140/unitedhealth-demands-rapid-repayment-of-cyberattack-relief-loan-billions-providers-say-push-undermines-recovery" target="_blank" rel="noreferrer noopener">UnitedHealth Demands Rapid Repayment Of Cyberattack Relief Loan Billions, Providers Say Push Undermines Recovery</a>
UnitedHealthcare&#8217;s first-quarter revenues of $84.6 billion grew by $9.3 billion year over year. Operating earnings were $5.2 billion, impacted by higher-than-expected care activity levels within its Medicare Advantage business.
<ul>
<li>The number of consumers served with self-funded commercial benefits increased by about 700,000. Commercial insured membership was impacted by attrition within individual exchange offerings due to a highly price-competitive marketplace.</li>
<li>The number of people served by the company&#8217;s offerings for seniors and people with complex needs grew by 545,000 and is expected to reach 800,000 in 2025.</li>
<li>People served by the company&#8217;s state-based community plans increased to 7.6 million members.</li>
</ul>
Optum&#8217;s first quarter revenues of $63.9 billion increased by $2.8 billion, led by Optum Rx. Operating earnings were $3.9 billion.
<ul>
<li>Optum Health&#8217;s revenues were $25.3 billion, and it expects to serve 650,000 new value-based care patients in 2025.</li>
<li>Optum Insight revenues were $4.6 billion and the revenue backlog was $32.9 billion.</li>
<li>Optum Rx revenues were $35.1 billion, with strong growth driven by new clients and expanded relationships with existing clients. Adjusted scripts grew to 408 million, compared to 395 million last year.</li>
</ul>
Guidance: UnitedHealth Group cuts its 2025 performance outlook. It expects adjusted earnings of $26.00-$26.50 per share versus <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43025159/unitedhealth-q4-earnings-revenue-falls-short-medical-ratio-rises-to-85-5-stock-falls" rel="noreferrer noopener">prior guidance of 29.50-$30.00</a> versus consensus of $29.73, reflecting:
<ul>
<li>Heightened care activity indications within UnitedHealthcare&#8217;s Medicare Advantage businesses became visible as the quarter closed, far above the planned 2025 increase consistent with the elevated levels in 2024.This activity was most notable within physician and outpatient services.</li>
<li>Unanticipated changes in the profile of Optum Health members impacting planned 2025 reimbursement due to unexpectedly minimal 2024 beneficiary engagement by plans exiting markets. In addition, a greater-than-expected impact to current and new complex patients from the ongoing Medicare funding reductions enacted by the previous administration.</li>
</ul>
Price Action: UNH stock is down 20.50% at $465 during the premarket session on the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44852717/earnings-preview-jpmorgan-bullish-on-atmos-amid-tariff-jitters-and-focus-on-ira-focus-more" target="_blank" rel="noreferrer noopener">JPMorgan Boosts Atmos Price Target, Reaffirms Bullish View On Spire And NJR</a></li>
</ul>
Photo by Ken Wolter via Shutterstock

Large Cap

Guidance

Health Care

Movers

Trading Ideas

UnitedHealth Slashes 2025 Outlook On Medicare Funding Reductions, Stock Crashes

B of A Securities analyst Ebrahim Poonawala maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Buy and raises the price target from $23 to $24.

B of A Securities Maintains Buy on First Horizon, Raises Price Target to $24

LLY: 14% &#x7C; <a href="https://www.benzinga.com/node/44859707">Eli Lilly shares are trading higher after the company announced topline Phase 3 results from its ACHIEVE-1 trial, which showed orforglipron demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines.</a>
&nbsp;
UNH: -20% &#x7C; <a href="https://www.benzinga.com/node/44859620">UnitedHealth shares are trading lower after the company reported worse-than-expected Q1 results and cut its FY25 adjusted EPS guidance below estimates.</a>
&nbsp;
HTZ: 120% &#x7C; <a href="https://www.benzinga.com/node/44859590">Hertz Global shares are trading higher after Pershing Square Capital Management disclosed a stake via a 13F. CNBC reported that Pershing Square's stake is 19.8%, through shares &amp; swaps.</a>

Market-Moving News for April 17th

Longbow Research analyst David Macgregor initiates coverage on Twin Disc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWIN#NASDAQ">TWIN</a>) with a Buy rating and announces Price Target of $12.

Initiation

TWIN

Longbow Research Initiates Coverage On Twin Disc with Buy Rating, Announces Price Target of $12

B of A Securities analyst Tim Anderson maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Underperform and lowers the price target from $575 to $547.

REGN

B of A Securities Maintains Underperform on Regeneron Pharmaceuticals, Lowers Price Target to $547

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the financial sector.
<h3 class="wp-block-heading">Annaly Capital Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>)</h3>
<ul>
<li>Dividend Yield: 15.88%</li>
<li>JP Morgan analyst Richard Shane maintained an Overweight rating and cut the price target from $21 to $19 on April 16, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Bose George maintained an Outperform rating and cut the price target from $21 to $20.15 on April 8, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: Annaly Capital Management will release its financial results for the quarter ended March 31, after the closing bell on Wednesday, April 30.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417">latest NLY news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417"><img loading="lazy" decoding="async" width="905" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17070257/image-1-6.png" alt="" class="wp-image-876303" style="width:553px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17070257/image-1-6.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17070257/image-1-6-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17070257/image-1-6-768x713.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<h3 class="wp-block-heading">PennantPark Investment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>)</h3>
<ul>
<li>Dividend Yield: 15.48%</li>
<li>Ladenburg Thalmann analyst Mickey Schleien downgraded the stock from Buy to Neutral on Nov. 27, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Compass Point analyst Casey Alexander upgraded the stock from Sell to Neutral with a price target of $6 on Sept. 9, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: PennantPark Investment will report results for the second fiscal quarter on Monday, May 12, after the close of the financial markets.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417">PNNT news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417"><img loading="lazy" decoding="async" width="898" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17070334/image-1-7.png" alt="" class="wp-image-876304" style="width:556px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17070334/image-1-7.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17070334/image-1-7-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17070334/image-1-7-768x707.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
<h3 class="wp-block-heading">New York Mortgage Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYMT#NASDAQ">NYMT</a>)</h3>
<ul>
<li>Dividend Yield: 15.01%</li>
<li>UBS analyst Douglas Harter maintained a Neutral rating and cut the price target from $7.5 to $6 on May 8, 2024. This analyst has an accuracy rate of 68%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Bose George maintained a Market Perform rating and cut the price target from $8.5 to $7 on May 3, 2024. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: New York Mortgage Trust will report financial results for the three months ended March 31, 2025 after the closing bell on April 30.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest NYMT <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417"><img loading="lazy" decoding="async" width="920" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17070418/image-17.png" alt="" class="wp-image-876305" style="width:505px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17070418/image-17.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17070418/image-17-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17070418/image-17-768x707.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44857276/netflix-unitedhealth-group-and-3-stocks-to-watch-heading-into-thursday">Netflix, UnitedHealth Group And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

NYMT

PNNT

Wall Street's Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 15% Dividend Yields

B of A Securities analyst Jason Kupferberg maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Buy and lowers the price target from $94 to $80.

B of A Securities Maintains Buy on Block, Lowers Price Target to $80

Keybanc analyst Noah Zatzkin upgrades YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) from Underweight to Sector Weight.

Upgrades

YETI

Keybanc Upgrades YETI Holdings to Sector Weight

American Express Sees FY25 EPS $15-$15.50 Vs $17.51 Estimate

Guidance for FY26: &nbsp;• Revenue growth of 0%-3% in constant currency • Operating margin of 20%-22%&nbsp;

INFY

Infosys Expects FY26 Revenue Growth Of 0.0%-3.0% In Constant Currency, Reiterated Operating Margin of 20%-22%

Buybacks

AVIR

Atea Pharmaceuticals Board authorizes Repurchase Of Up To $25M Of Common Stock

A federal labor agency has found itself at the center of a cybersecurity controversy after a whistleblower alleged DOGE workers set off a major data breach.
The allegations, shared with Congress and made public by Whistleblower Aid, indicate unauthorized access and possible data exfiltration from the National Labor Relations Board (NLRB).
What Happened: Daniel Berulis, an IT staffer at the NLRB, said in an affidavit that the DOGE Service team was given wide-ranging access to internal systems.
He reported unusual activity beginning in March, such as tampered logging protocols and the removal of roughly 10 gigabytes of sensitive data. NPR <a href="https://www.npr.org/2025/04/15/nx-s1-5355896/doge-nlrb-elon-musk-spacex-security">reported</a> that the files seemingly included private affidavits, union-related information, and proprietary business documents.
See Also: <a href="https://www.benzinga.com/25/04/44857730/elon-musks-team-reportedly-installs-satellite-equipment-at-key-federal-agency-raising-oversight-questions">Elon Musk&#8217;s Team Installs Starlink Satellite Equipment At Key Federal Agency: Report</a>
Why It Matters: The NLRB deals with confidential labor complaints and union organizing data. Breaches like these could jeopardize investigations and expose sensitive corporate and worker information. Berulis also made note of attempted logins from a Russian IP address using valid credentials, raising further red flags about security conditions.
Berulis said efforts to report the incident to federal cybersecurity authorities were resisted by agency leadership, and that he had received a threatening message at his home.
Following the disclosure, NPR <a href="https://www.npr.org/2025/04/16/nx-s1-5366851/doge-nlrb-whistleblower-musk-data">reported</a> that DOGE allocated two staffers to work part-time at the NLRB.
DOGE has been previously linked with privacy and security concerns across other federal agencies, such as its attempts to access<a href="https://www.benzinga.com/personal-finance/25/04/44697671/trump-administrations-push-to-access-social-security-data-faces-major-setback-as-court-dismisses-appeal"> data from the Social Security Administration</a>, <a href="https://www.benzinga.com/news/25/02/43768756/privacy-concerns-emerge-as-elon-musks-doge-team-seeks-access-to-taxpayer-data">taxpayer data</a>, and its reported <a href="https://www.benzinga.com/politics/25/04/44683851/elon-musks-secretive-doge-team-using-ai-and-disappearing-messages-to-monitor-federal-workers-for-anti-trump-sentiment-bypassing-records-laws-and-locking-out-agencies-report">tracking of employee communications using AI tools.</a>
These latest developments have coincided with news that Elon Musk has reportedly slashed DOGE's projected federal budget savings target from <a href="https://www.benzinga.com/25/04/44759007/did-elon-musk-just-lower-doges-1-trillion-savings-target-to-150-billion-in-a-second-revision-since-jan">$1 trillion to $150 billion</a> for 2026, making this the second revision amid increasing scrutiny over inflated savings claims and economic risks.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/04/44835225/netflixs-black-mirror-returns-with-grim-warning-about-life-trapped-behind-endless-paywalls">Netflix&#8217;s &#8216;Black Mirror&#8217; Returns With Grim Warning About Life Trapped Behind Endless Paywalls</a></li>
</ul>
Photo courtesy: Shutterstock

Politics

Tech

Whistleblower Says DOGE May Have Caused Major Cybersecurity Breach At US Labor Agency

FDA Accepts Regeneron's EYLEA HD Injection 8 mg sBLA For Priority Review For Treatment Of Macular Edema Following Retinal Vein Occlusion And For Monthly Dosing In Approved Indications

Cannabis

Stock Split

TLRY

Tilray Brands To Vote For Implementation Of Reverse Stock Split At A Ratio Ranging From 1-to-10 To 1-to-20

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025
GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis
Nurix to receive a $5 million milestone payment from Gilead for FDA clearance of the IND, bringing the total amount received under the 2019 collaboration agreement to $135 million
Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the IRAK4 degrader program as well as potential future royalties and retains an option to co-develop and co-detail in the United States with the parties splitting U.S. profits and losses
SAN FRANCISCO, April 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared the IND for the IRAK4 degrader GS-6791/NX-0479, enabling the initiation of a Phase 1 trial, which is anticipated to begin in Q2 2025.

Comments

Aurora Innovation

Notizie

Ultime notizie per Aurora Innovation (NASDAQ:AUR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO